Skip Navigation LinksSkip Navigation Links
Centers for Disease Control and Prevention
Safer Healthier People
Blue White
Blue White
bottom curve
CDC Home Search Health Topics A-Z spacer spacer
Blue curve MMWR spacer

Epidemiologic Notes and Reports Antibody Response to A/Taiwan/ 86 (H1N1) Virus in Young Adults Receiving Supplemental Monovalent A/ Taiwan/86 Influenza Vaccine Following Trivalent Influenza Vaccine

In accordance with recent recommendations (1), monovalent A/Taiwan/86 (H1N1) influenza vaccine was given to U.S. Air Force recruits who had been vaccinated 2 to 3 months previously with the 1986/87 trivalent influenza vaccine. Thirty-four recruits volunteered sera for antibody studies of immune response. At the time the A/Taiwan/86 vaccine was administered, 100% of the recruits had serum hemagglutination-inhibition (HI) antibody titers of greater than or equal to 32 to the A/Chile/83 (H1N1) virus included in the trivalent vaccine, but only 45% had such titers to the A/Taiwan/86 strain. Following immunization with the supplemental monovalent vaccine, the proportion of recruits with HI antibody titers of greater than or equal to 32 against A/Taiwan/86 virus increased to 100%, and 92% had HI titers greater than or equal to 128 (Table 1). Reported by G Meiklejohn, MD, Patricia Graves, School of Medicine, Univ of Colorado Health Sciences Center, Denver, Col G Hutchison, Lowry Air Force Base, Colorado; Lt Col M Evans, MD, Lackland Air Force Base, Texas; Influenza Br, Div of Viral Diseases, Center for Infectious Diseases, CDC.

Editorial Note

Editorial Note: The above findings are consistent with previous reports (2,3) that the A/Chile/83 component of the 1986/87 trivalent vaccine may provide inadequate protection against the A/Taiwan/86 virus; protection may be boosted by use of the monovalent A/Taiwan/86 vaccine as recommended (1). Because all recently reported outbreaks of influenza A/Taiwan/86-like virus, where laboratory confirmation has been obtained, have occurred in children or young adults, it is particularly important that high-risk individuals in these age groups be given priority for vaccination with the supplemental A/Taiwan/86 vaccine. (See "Update of Influenza Activity, Availability of Influenza Vaccines, and Recommendations and Precautions for the Use of Amantadine", pp. 805-807.)


  1. ACIP. Monovalent influenza A(H1N1) vaccine, 1986-87. MMWR 1986;35:517-21.

  2. CDC. Antigenic variation of recent influenza A(H1N1) viruses. MMWR 1986;35:510-2.

  3. CDC. Influenza activity in civilian and military populations and key points for use of influenza vaccines. MMWR 1986;35:729-31.

Disclaimer   All MMWR HTML documents published before January 1993 are electronic conversions from ASCII text into HTML. This conversion may have resulted in character translation or format errors in the HTML version. Users should not rely on this HTML document, but are referred to the original MMWR paper copy for the official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to

Page converted: 08/05/98


Safer, Healthier People

Morbidity and Mortality Weekly Report
Centers for Disease Control and Prevention
1600 Clifton Rd, MailStop E-90, Atlanta, GA 30333, U.S.A


Department of Health
and Human Services

This page last reviewed 5/2/01